Study S000212

A Phase 1, Randomized, Double-blind, Multiple-dose Study to Evaluate the Pharmacokinetics of AMG 133 Administered Subcutaneously in Subjects With Overweight or Obesity

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT06976372
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: DOUBLE
Status: COMPLETED
Enrollment: 120
Start: 2024-08-20
Primary completion: 2024-12-27
Lead sponsor: Amgen
Conditions: Overweight; Obesity
Interventions: DRUG:AMG 133
Results posted: FALSE
Individual participant data sharing: YES

Registered primary outcomes

Maximum Concentration (Cmax) of AMG 133 [Up to Day 99]
Area Under the Plasma Concentration-time Curve from Time Zero to the Last Quantifiable Concentration (AUClast) of AMG 133 [Day 29]
Area Under the Plasma Concentration-time Curve from Time Zero to Infinity (AUCinf) of AMG 133 [Day 29]
Area Under the Plasma Concentration-time Curve Over the Dosing Interval (AUCtau) of AMG 133 [Day 1 and Day 15]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.